长江生命科技发盈警 预计中期取得股东应占亏损约1.5亿港元 同比盈转亏

Core Viewpoint - Changjiang Life Science Technology (00775) expects to report a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024, primarily due to the company's decision to increase R&D investment [1] Group 1 - The expected shareholder loss of HKD 150 million marks a significant shift from the previous year's profit of HKD 1 million [1] - The company's operational performance has remained stable during the reporting period and up to the date of this announcement [1]